PMID- 28353192
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20181202
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 106
IP  - 4
DP  - 2017 Oct
TI  - Three cases of relapsed/refractory multiple myeloma under hemodialysis treated 
      with panobinostat/bortezomib/dexamethasone (FVD).
PG  - 581-587
LID - 10.1007/s12185-017-2222-4 [doi]
AB  - Three patients under hemodialysis (HD) with relapsed/refractory multiple myeloma 
      (MM) were administered panobinostat/bortezomib/dexamethasone (FVD). Case 1: The 
      patient was a 66-year-old male with BJP-kappa. FVD was effective, but HD could not be 
      discontinued. He developed Grade 3 adverse events (AEs), including nausea, 
      dehydration, and fatigue, following the common terminology criteria for adverse 
      events v4.0. FVD was discontinued after the third course, while HD was continued. 
      Case 2: The patient was a 65-year-old female with IgG-lambda + BJP-lambda. Amyloidosis was 
      complicated. The first course of FVD was effective, but HD could not be 
      discontinued. She developed G2 AEs, including nausea and fatigue. The cardiac 
      amyloidosis worsened, and she died of heart and renal failure. Case 3: The 
      patient was a 79-year-old male with BJP-kappa. FVD was effective, and the HD could be 
      discontinued on day 12 of treatment. No AEs were noted. However, he declined 
      continuation of the FVD and died of MM relapse and renal failure. We analyzed the 
      pharmacokinetics of panobinostat. There were no correlations between dose level 
      and blood level of panobinostat or between blood level, efficacy, and incidence 
      of AEs. We additionally measured the rate of elimination of the drug by HD.
FAU - Sekiguchi, Yasunobu
AU  - Sekiguchi Y
AD  - Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, 
      Urayasu, Chiba, Japan. yasu_sek@juntendo-urayasu.jp.
FAU - Takizawa, Haruko
AU  - Takizawa H
AD  - Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, 
      Urayasu, Chiba, Japan.
FAU - Inano, Tadaaki
AU  - Inano T
AD  - Department of Hematology, Juntendo University Hospital, Tokyo, Japan.
FAU - Fukuda, Yasutaka
AU  - Fukuda Y
AD  - Department of Hematology, Juntendo University Hospital, Tokyo, Japan.
FAU - Wakabayashi, Mutsumi
AU  - Wakabayashi M
AD  - Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, 
      Urayasu, Chiba, Japan.
FAU - Sugimoto, Keiji
AU  - Sugimoto K
AD  - Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, 
      Urayasu, Chiba, Japan.
FAU - Tomita, Shigeki
AU  - Tomita S
AD  - Department of Pathology, Juntendo University Urayasu Hospital, Urayasu, Japan.
FAU - Izumi, Hiroshi
AU  - Izumi H
AD  - Department of Pathology, Juntendo University Urayasu Hospital, Urayasu, Japan.
FAU - Nakamura, Noriko
AU  - Nakamura N
AD  - Department of Clinical Laboratory, Juntendo University Urayasu Hospital, Urayasu, 
      Japan.
FAU - Sawada, Tomohiro
AU  - Sawada T
AD  - Department of Clinical Laboratory, Juntendo University Urayasu Hospital, Urayasu, 
      Japan.
FAU - Ohta, Yasunori
AU  - Ohta Y
AD  - Department of Pathology, The Institute of Medical Science, The University of 
      Tokyo, Tokyo, Japan.
FAU - Komatsu, Norio
AU  - Komatsu N
AD  - Department of Hematology, Juntendo University Hospital, Tokyo, Japan.
FAU - Noguchi, Masaaki
AU  - Noguchi M
AD  - Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, 
      Urayasu, Chiba, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20170328
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Hydroxamic Acids)
RN  - 0 (Indoles)
RN  - 69G8BD63PP (Bortezomib)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 9647FM7Y3Z (Panobinostat)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & 
      dosage/*pharmacokinetics
MH  - Bortezomib/administration & dosage/pharmacokinetics
MH  - Dexamethasone/administration & dosage/pharmacokinetics
MH  - Female
MH  - Humans
MH  - Hydroxamic Acids/administration & dosage/pharmacokinetics
MH  - Indoles/administration & dosage/pharmacokinetics
MH  - Male
MH  - Multiple Myeloma/blood/*therapy
MH  - Panobinostat
MH  - Recurrence
MH  - *Renal Dialysis
MH  - Renal Insufficiency/blood/*therapy
OTO - NOTNLM
OT  - Hemodialysis
OT  - Panobinostat/bortezomib/dexamethasone (FVD) therapy
OT  - Relapsed/refractory multiple myeloma
OT  - Renal failure
EDAT- 2017/03/30 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/03/30 06:00
PHST- 2017/01/27 00:00 [received]
PHST- 2017/03/24 00:00 [accepted]
PHST- 2017/03/21 00:00 [revised]
PHST- 2017/03/30 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
PHST- 2017/03/30 06:00 [entrez]
AID - 10.1007/s12185-017-2222-4 [pii]
AID - 10.1007/s12185-017-2222-4 [doi]
PST - ppublish
SO  - Int J Hematol. 2017 Oct;106(4):581-587. doi: 10.1007/s12185-017-2222-4. Epub 2017 
      Mar 28.